F 1 (SJL/J × C57BL/6) mice with MOG35-55-induced EAE recover from disease when treated with Ig-MOG carrying MOG35-55 peptide. However, Ig-PLP1, carrying PLP139-151, induced reduction of anti-MOG antibodies and exacerbated EAE. Herein, we show that Ig-PLP1 specifically reduces the frequency of B cells producing protective IgG2a/b anti-MOG antibodies. Surprisingly, these cells were marginal zone (MZ), rather than follicular (FO) or newly formed (NF), B cells and transfer of MZ B cells into sick mice nullified disease exacerbation by Ig-PLP1 in a complement dependent manner. These findings reveal a potential self-limiting regulatory mechanism involving auto-antibodies in MOG EAE.
Introduction
In previous studies we have shown that Ig-PLP1, expressing the H-2 s restricted proteolipid protein (PLP) peptide 139-151, is able to suppress relapses of PLP1-induced EAE (Legge et al., 2000) . Aggregation of the chimera further enhances its tolerogenic function and modulates both the initial severe phase of EAE as well as the subsequent relapses (Legge et al., 2000) . Moreover, aggregated (agg) Ig-PLP1 displayed effective bystander suppression and was able to counter disease induced by central nervous system (CNS) homogenate, which involves diverse T specificities (Legge et al., 2000) . Similarly, Ig-MOG, carrying the H-2 b restricted myelin oligodendrocyte glycoprotein (MOG) 35-55 peptide, is able to inhibit MOG-induced EAE (Legge et al., 2002) . In addition agg Ig-MOG also displays bystander suppression and ameliorates CNS homogenate-induced EAE (Legge et al., 2002) . Given this efficacy we tested the chimera for suppression of disease under circumstances relevant to human polymorphism. Indeed, when (SJL/J × C57BL/6) F 1 mice, which carry both parental haplotypes, were induced for EAE with PLP1 peptide, both agg IgPLP1 and Ig-MOG were able to modulate the disease (Bell et al., 2008) . This suggested that Ig-PLP1 sustains cis while Ig-MOG supports in trans tolerance to modulate PLP-1 specific T cells (Bell et al., 2008) . However, when disease was induced with MOG peptide, cis tolerance was effective and Ig-MOG was able to modulate EAE, but in trans tolerance was non-functional and agg Ig-PLP1 exacerbated MOG EAE (Bell et al., 2008) . Initial investigation of the mechanism underlying exacerbation of MOG EAE by treatment with agg Ig-PLP1 indicated that the regimen induced IL-5 production by PLP1-specific T cells, which led to inhibition of the production of anti-MOG antibodies by B cells (Bell et al., 2008) . Herein, we show that exacerbation of EAE is due to a specific suppression of protective anti-MOG antibodies that otherwise contribute to disease resolution. Given that the protective anti-MOG antibodies were of the IgG2a/b isotype, and Ig switching requires interaction of B and T cells, we envisioned that FO B cells would be the subset producing the protective anti-MOG antibodies. The results, however, indicated that marginal zone (MZ), but not follicular (FO) or newly formed (NF), IgG2a/b + B cells produce protective anti-MOG antibody and, upon transfer these MZ B cells sustain disease resolution in a complement dependent manner. These findings reveal a potential self-limiting regulatory mechanism of MOG EAE in F 1 mice in which MOG specific B cells produce auto-antibodies that contribute to disease resolution rather than pathogenesis, which may have important implications for the design of antigen specific therapies.
Materials and methods

Animals
SJL/J (H-2 s ) and C57BL/6 (H-2 b ) mice were purchased from The Jackson Laboratory. F 1 (SJL/J × C57BL/6) mice were generated by Journal of Neuroimmunology 266 (2014) 49-55 
